Biolase News

Ascendiant Capital Maintains Buy on Biolase, Lowers Price Target to $4

BenzingaApr 1 17:40

Biolase Analyst Ratings

BenzingaApr 1 17:38

Biolase's Strong Q4 Performance and Positive 2024 Outlook Affirm Buy Rating

TipRanksMar 23 19:35

Biolase Analyst Ratings

BenzingaMar 23 01:37

Maxim Group Reaffirms Their Buy Rating on Biolase (BIOL)

TipRanksFeb 23 05:05

Positive Clinical Trial Results and Successful Cost Optimization Initiatives Bolster Buy Rating for Biolase Despite Lowered Price Target

TipRanksNov 15, 2023 02:15

Positive McGuire Study Results Boost Biolase's Market Potential and Justify Buy Rating

TipRanksNov 10, 2023 02:46

Maxim Group Sticks to Their Buy Rating for Biolase (BIOL)

TipRanksJun 7, 2023 19:45

Lake Street Adjusts Price Target on Biolase to $0.40 From $1.50, Maintains Buy Rating

MT NewswiresMay 31, 2023 21:51

Lake Street Maintains Buy on Biolase, Lowers Price Target to $0.4

BenzingaMay 31, 2023 21:28

Lake Street Remains a Buy on Biolase (BIOL)

TipRanksMar 29, 2023 21:36

Benchmark Reiterates Speculative Buy on Biolase, Maintains $2 Price Target

BenzingaMar 29, 2023 20:00

Biolase Analyst Ratings

Benzinga Analyst RatingsJan 20, 2023 22:01

Maxim Group Sticks to Their Buy Rating for Biolase (BIOL)

TipRanksJan 20, 2023 03:50